A pharmacist-focused view of how repetitive medication alerts consume verification time, where software still lacks patient-specific clinical context, how AI and automation are entering dispensing workflows, and what pharmacists need before routine verification can safely become more autonomous.
Audience: Pharmacists
Countries: 6
Completion Rate: 83.1%
SGID: 8953041
-Hero findings
– Quick Read — Key Findings
Prescription verification sits at the intersection of clinical decision support, laboratory data, medication history, product identity, dispensing technology, and professional judgment. Alerts can protect patients when they surface the right risk at the right moment. They can also create extra work when warnings are repetitive, overly broad, or disconnected from the patient in front of the pharmacist.
External safety guidance reflects that tension. The Institute for Safe Medication Practices recommends reducing invalid, insignificant, or overly sensitive computer alerts, and the American Society of Health-System Pharmacists says pharmacists should help decide which medication-use tasks are best handled by people, by AI, or by both. The question is not whether to use technology, but how to make it clinically selective enough to protect attention as well as safety.
31.9% estimate that 50% to 74% of drug-interaction or dosing alerts are clinically irrelevant or overridden in daily practice.
The largest band is 50% to 74%, then 25% to 49% at 23.2%, with 15.2% at 75% to 89% and 10.1% at 90% or more, while 15.9% see fewer than one in four as irrelevant and 3.6% do not track override rates. The share reporting a majority-override environment far outweighs the low end, which is the crux of the fatigue problem.
34.1% estimate spending 15 to 30 minutes per shift reviewing and clearing repetitive or low-value software alerts.
Another 23.9% estimate 31 to 60 minutes and 15.2% more than an hour, while only 26.8% stay under 15 minutes, so most pharmacists lose a meaningful slice of every shift to alert review. That cost is not just elapsed time, because each alert lands mid-verification, competing with dosing checks, prescriber contact, and counseling.
49.3% describe their software as ineffective or non-existent at using current patient lab values to adjust or suppress dosing alerts.
Only 8.0% call their system highly effective at calculating adjustments automatically from the latest EHR labs, while 26.8% flag abnormal values but still require manual calculation and 15.9% say alerts often miss updated labs. With nearly half rating context integration as ineffective, the smartness gap sits in the data plumbing, not the alert rules.
54.3% say their health system or pharmacy software still relies on legacy, rule-based alerts.
Fully operational AI/ML suppression is reported by 10.1%, active pilots by 11.6%, planned deployment by 8.0%, and 15.9% are unsure, so barely a third are even moving toward AI suppression. The autonomy debate is running ahead of the infrastructure, since most respondents still sit on legacy, rule-based alerts.
42.0% rely on pharmacist-only visual inspection to confirm that physical drug contents match the prescribed order before final dispensing.
Barcode scanning of stock bottles or vials follows closely at 40.6%, AI computer vision at 10.1%, automated central fill or robotic dispensing at 4.3%, and other methods at 2.9%. With roughly 83% relying on the pharmacist’s eyes or a barcode as the final check, AI vision remains a supplement, not the safety net.
34.8% somewhat support autonomous AI pre-verification only for specific maintenance drug classes under strict protocols.
Strong support is 13.8%, neutral 18.1%, somewhat opposed 26.1%, and strongly opposed 7.2%, so the largest group backs AI pre-verification only with clear restrictions. That caution fits the barriers: 57.2% cite the risk of missing a critical warning and the same share cite legal and clinical liability, so the resistance is about accountability, not novelty.
The survey does not describe pharmacists rejecting technology. It describes professionals who already work inside highly computerized medication-use systems and can see exactly where they fall short: alerts remain noisy, real-time clinical data are poorly integrated, and the final physical check still leans on human inspection or barcodes.
That is why support is conditional. Pharmacists are most open when the task is routine, the protocol narrow, the system auditable, and a human can step in when the case stops being routine. The next phase may be less about replacing verification than making it selective: fewer low-value interruptions, stronger patient-specific context, clearer escalation, and evidence that the technology knows when to defer.
You have read the summary
Common questions about medication alerts, clinical decision support, AI-assisted prescription verification, and pharmacist oversight.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
